Total Payments
$465,903
2024 Payments
$34,937
Companies
81
Transactions
1,643
Medicare Patients
2,921
Medicare Billing
$608,078
Payment Breakdown by Category
Other$311,919 (66.9%)
Consulting$66,947 (14.4%)
Travel$51,490 (11.1%)
Food & Beverage$31,559 (6.8%)
Research$2,181 (0.5%)
Education$1,808 (0.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $310,987 | 126 | 66.7% |
| Consulting Fee | $66,947 | 33 | 14.4% |
| Travel and Lodging | $51,490 | 206 | 11.1% |
| Food and Beverage | $31,559 | 1,223 | 6.8% |
| Unspecified | $2,181 | 2 | 0.5% |
| Education | $1,808 | 43 | 0.4% |
| Long term medical supply or device loan | $931.52 | 10 | 0.2% |
Payments by Type
General
$463,723
1,641 transactions
Research
$2,181
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $134,556 | 223 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $86,798 | 120 | $0 (2024) |
| Genentech USA, Inc. | $81,104 | 117 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $39,954 | 167 | $0 (2024) |
| Merck Sharp & Dohme LLC | $34,552 | 89 | $0 (2024) |
| Amgen Inc. | $33,419 | 79 | $0 (2024) |
| GENZYME CORPORATION | $7,895 | 27 | $0 (2024) |
| ABBVIE INC. | $6,762 | 29 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $4,770 | 7 | $0 (2022) |
| Incyte Corporation | $4,040 | 29 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $34,937 | 234 | Regeneron Healthcare Solutions, Inc. ($27,218) |
| 2023 | $65,619 | 276 | Regeneron Healthcare Solutions, Inc. ($43,685) |
| 2022 | $61,743 | 239 | Amgen Inc. ($22,517) |
| 2021 | $5,068 | 156 | GENZYME CORPORATION ($851.64) |
| 2020 | $14,638 | 149 | AstraZeneca Pharmaceuticals LP ($5,277) |
| 2019 | $48,831 | 153 | AstraZeneca Pharmaceuticals LP ($28,203) |
| 2018 | $85,532 | 185 | AstraZeneca Pharmaceuticals LP ($36,014) |
| 2017 | $149,536 | 251 | AstraZeneca Pharmaceuticals LP ($62,001) |
All Payment Transactions
1,643 individual payment records from CMS Open Payments — Page 1 of 66
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/22/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $21.24 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $31.82 | General |
| Category: Bone Health | ||||||
| 12/17/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $23.66 | General |
| Category: Oncology | ||||||
| 12/12/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $26.80 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | ARRAY BIOPHARMA INC | BRAFTOVI (Drug), MEKTOVI, TUKYSA | Food and Beverage | In-kind items and services | $17.91 | General |
| Category: ONCOLOGY | ||||||
| 12/12/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $3.51 | General |
| Category: ONCOLOGY | ||||||
| 12/11/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $29.18 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,605.00 | General |
| Category: ONCOLOGY | ||||||
| 12/10/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $17.16 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 12/10/2024 | Rigel Pharmaceuticals, Inc. | Rezlidhia (Drug), Tavalisse | Food and Beverage | Cash or cash equivalent | $14.95 | General |
| Category: Acute Myeloid Leukemia | ||||||
| 12/09/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $25.86 | General |
| Category: Iron Deficiency Anemia | ||||||
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $13.74 | General |
| Category: Oncology | ||||||
| 12/05/2024 | Coherus Biosciences Inc. | LOQTORZI (Biological) | Food and Beverage | In-kind items and services | $30.42 | General |
| Category: Oncology | ||||||
| 12/04/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological), ZEJULA | Food and Beverage | In-kind items and services | $22.37 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $24.11 | General |
| Category: HORMONE THERAPY | ||||||
| 11/22/2024 | Celgene Corporation | OPDUALAG (Drug) | Food and Beverage | Cash or cash equivalent | $23.70 | General |
| Category: Oncology | ||||||
| 11/22/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $15.26 | General |
| Category: ONCOLOGY | ||||||
| 11/21/2024 | Octapharma USA, Inc. | OCTAGAM IMMUNE GLOBULIN (HUMAN) (Biological) | Food and Beverage | In-kind items and services | $52.66 | General |
| Category: IMMUNOLOGY | ||||||
| 11/20/2024 | Genentech USA, Inc. | Ocrevus Zunovo (Biological) | Food and Beverage | In-kind items and services | $31.70 | General |
| Category: Immunology | ||||||
| 11/19/2024 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $33.70 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $23.45 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Janssen Biotech, Inc. | TECVAYLI (Biological) | Food and Beverage | In-kind items and services | $1.14 | General |
| Category: Oncology | ||||||
| 11/12/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $24.80 | General |
| Category: Hematology | ||||||
| 11/12/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $10.90 | General |
| Category: Oncology | ||||||
| 11/11/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $70.71 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EMBER-4: A RANDOMIZED OPEN-LABEL PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATIENTS WHO HAVE PREVIOUSLY RECEIVED 2 TO 5 YEARS OF ADJUVANT ENDOCRINE THERAPY FOR ER+ HER2- EARLY BREAST CANCER WITH AN INCREASED RISK OF RECURRENCE | Eli Lilly and Company | $2,070 | 1 |
| PCYC-1128-CA | Pharmacyclics LLC, An AbbVie Company | $110.13 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 614 | 1,342 | $614,981 | $131,307 |
| 2022 | 9 | 703 | 1,622 | $711,186 | $152,704 |
| 2021 | 9 | 803 | 1,818 | $774,985 | $171,814 |
| 2020 | 10 | 801 | 1,898 | $714,226 | $152,254 |
Total Patients
2,921
Total Services
6,680
Medicare Billing
$608,078
Procedure Codes
50
All Medicare Procedures & Services
50 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 243 | 650 | $305,500 | $70,840 | 23.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 129 | 303 | $142,239 | $23,498 | 16.5% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 44 | 148 | $45,288 | $10,312 | 22.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 40 | 40 | $28,400 | $5,235 | 18.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 25 | 25 | $22,150 | $4,904 | 22.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 24 | 26 | $16,432 | $4,256 | 25.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 30 | 32 | $18,112 | $3,563 | 19.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 23 | 50 | $11,140 | $2,782 | 25.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 22 | 22 | $15,620 | $2,478 | 15.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 15 | 24 | $7,680 | $1,877 | 24.4% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 19 | 22 | $2,420 | $1,562 | 64.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 229 | 662 | $311,140 | $71,435 | 23.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 120 | 331 | $154,740 | $25,845 | 16.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 73 | 285 | $87,210 | $17,855 | 20.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 61 | 61 | $43,310 | $8,714 | 20.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 44 | 44 | $24,904 | $5,232 | 21.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 48 | 67 | $21,440 | $5,147 | 24.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 23 | 23 | $20,378 | $4,701 | 23.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 22 | 24 | $15,168 | $4,021 | 26.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 24 | 32 | $5,312 | $3,144 | 59.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 24 | 53 | $12,384 | $3,033 | 24.5% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 18 | 18 | $12,780 | $2,019 | 15.8% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 17 | 22 | $2,420 | $1,556 | 64.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 240 | 675 | $317,250 | $75,747 | 23.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 123 | 369 | $173,250 | $30,003 | 17.3% |
About Dr. Robert Weber, MD
Dr. Robert Weber, MD is a Hematology & Oncology healthcare provider based in Daly City, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 11/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1265505291.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Weber, MD has received a total of $465,903 in payments from pharmaceutical and medical device companies, with $34,937 received in 2024. These payments were reported across 1,643 transactions from 81 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($310,987).
As a Medicare-enrolled provider, Weber has provided services to 2,921 Medicare beneficiaries, totaling 6,680 services with total Medicare billing of $608,078. Data is available for 4 years (2020–2023), covering 50 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Other Specialties Hematology & Oncology
- Location Daly City, CA
- Active Since 11/16/2006
- Last Updated 07/21/2022
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1265505291
Products in Payments
- LIBTAYO (Biological) $94,280
- TAGRISSO (Drug) $71,113
- TECENTRIQ (Biological) $69,835
- IMFINZI (Drug) $60,553
- OPDIVO (Biological) $38,178
- KEYTRUDA (Biological) $31,331
- LUMAKRAS (Drug) $22,954
- VENCLEXTA (Drug) $6,584
- Alecensa (Biological) $6,481
- GILOTRIF (Drug) $4,744
- Avastin (Biological) $3,835
- Yescarta (Drug) $3,016
- ZEJULA (Drug) $2,825
- CALQUENCE (Drug) $2,237
- PROMACTA (Drug) $2,049
- Cabometyx (Drug) $1,928
- Nerlynx (Drug) $1,163
- KISQALI (Drug) $1,062
- IMBRUVICA (Drug) $996.98
- IBRANCE (Drug) $709.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.